In order to tailor the site to your needs, please click the button that relates best to you.
So long as you have cookies enabled you will only need to do this once. However, you can change your selection at any time using the dropdown navigation option above the CESPHN logo, top left.
This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
Recommended interval between AstraZeneca vaccine doses in outbreak situations
On 13 July, ATAGI released a statement which recommends that in outbreak situations, a shorter interval of 4 to 8 weeks is preferred between the first and second doses of COVID-19 Vaccine AstraZeneca. Shortening the gap between first and second doses will bring forward short term protection, which is expected to be beneficial in outbreak situations.
In non-outbreak settings, the preferred interval between doses of COVID-19 Vaccine AstraZeneca remains at 12 weeks.
Who is eligible to receive the Pfizer COVID-19 vaccine?
The following people are currently eligible for the Pfizer vaccine:
This new clinical guideline for health professions outlines the primary care approach to identifying, diagnosing and treating thrombosis with thrombocytopenia syndrome (TTS) after COVID-19 AstraZeneca vaccine.
Key messages
Primary health care providers should consider the potential for a patient having TTS if they present with possible thrombosis or thrombocytopenia 4-42 days after they have received a dose of the AstraZeneca vaccine.
Suspected cases should be immediately referred to an emergency department if they are acutely unwell (for example, they have a neurological deficit).
Prioritisation of residential aged care workers is particularly important given it will be mandatory for all aged care workers to have received a minimum first dose COVID-19 vaccine by 17 September as a condition of employment.
Vaccination sites are requested to facilitate access to a vaccine booking (with AstraZeneca or Pfizer if available) withintwo weeks upon receiving a request from an aged care worker where possible. All aged care workers, regardless of age, can access the Pfizer vaccine.
Home visits for patients who cannot attend a clinic
Both the Pfizer and AstraZeneca COVID-19 vaccines are in multi-dose vials. This may make it challenging to administer vaccines off-site such as for home visits, or at residential aged care or disability accommodation facilities. The following advicehas been provided for vaccine providers for administering COVID-19 vaccines off-site:
transport the vial and draw up the dose at the site of administration. For the Pfizer vaccine, you can either dilute the vaccine in your practice or at the site of administration
transport pre-drawn doses if you can appropriately store the vaccine and deliver it promptly. This means protecting the vaccine from light and maintaining appropriate cold chain. This also means delivering the vaccine within one hour if kept at room temperature, or six hours if stored at 2-8°C. If you cannot ensure these conditions, you should transport the vial and draw up the dose on site.
You must ensure that each vial or dose is stored at the recommended temperature and does not exceed the total maximum storage period specified in the Product Information. See AstraZeneca product information and Pfizer product information. ATAGI recommends that, when possible, pre-drawn doses kept at room temperature be used within an hour to minimise any remote potential risk of infection. See Transporting, storing and handling vaccines p20
MBS item numbers that can be claimed for COVID-19 vaccination home visits:
90005 Flag fall service Fee: $67.35 Benefit: 85% = $57.25
The ATAGI clinical statement provides recommendations for the two zoster vaccines now available for use, Zostavax and Shingrix.
Shingrix is preferred over Zostavax from age 50 years and above for prevention of herpes zoster and its complications, due to its higher efficacy. However, availability is expected to be limited, and it needs to be privately prescribed.
Zostavax remains a readily available and effective alternative vaccine for immunocompetent adults aged ≥50 years who wish to reduce their risk of herpes zoster. It is recommended and funded under the National Immunisation Program (NIP) for immunocompetent people aged 70 years of age (with catch-up for those aged 71-79 years until October 2021).
Where to report a cold chain breach
Cold chain breach of all COVID-19 vaccines should be reported to the Vaccine Operations Centre (VOC) on 1800 318 208. VOC hours of operation are from 7am to 10pm AEST, or email COVID19VaccineOperationsCentre@Health.gov.au.
Cold chain breach of National Immunisation Program (NIP) vaccines should be reported to the Public Health Unit (PHU). Fill out the Cold chain breach and vaccine wastage reporting form and submit to PHU along with data logger report and temperature chart.
For privately purchased vaccines, contact the vaccine manufacturer for further advice following a cold chain breach.
Mandatory reporting of all nip vaccines
From 1 July 2021, vaccination providers are required to report all National Immunisation Program (NIP) vaccines administered to the Australian Immunisation Register (AIR) within 24 hours, and no more than 10 working days after the vaccination.
Health professionals should use the latest version of their clinical software to make sure they meet reporting requirements.
Welcome to our new website! As you may have noticed, our website looks different. Central and Eastern Sydney PHN have moved to a new site and although much has remained the same, we have introduced some new functions. These include: Updated navigation When you land on our new website, you…
COVID-19 weekly update – 02 JANUARY 2023 COVID-19 cases in the region Please note: From next week the latest COVID-19 information will be included in the Sydney Health Weekly newsletter, rather than separated at the top. We will still provide COVID-19 related information as well as the dedicated COVID-19 latest…
FIVE QUESTIONS is where we ask members of the community to talk about how they stay HEALTHY. Randwick scientist and grandmother Hilda Stender shared this: What exercise did you do yesterday? I’ve had two knee replacements – one four years ago and the other six months ago. As a result,…
Immunisation weekly update – 1 February 2023 Childhood immunisation overdue reports CESPHN is inviting general practices to sign up to receive a regular report extracted on your behalf from the Australian Immunisation Register (AIR) which is specific to your practice. This report contains all children aged 0-5 living in the CESPHN region…
Australian Digital Health Agency (ADHA) digital health webinars Implementing MyHealth Record Policies in your organisation Thu 9 Feb 23, 12.30-1.00 pm – learn how to implement and maintain a My Health Record Security and Access policy in your organisation. Understand the importance of the Responsible Officer (RO) and Organisational Maintenance…
UNSW research – Palliative care and intellectual disability A research team led by Professor Julian Trollor at the Department of Developmental Disability Neuropsychiatry, UNSW Sydney, aims to design, implement, and evaluate a new palliative care service for people with intellectual disability. This is important because people with intellectual disability often…
GP support needed: Shared e-Care plan study for follow-up of colorectal and breast cancers This research evaluates shared care using a new interactive e-care plan being implemented through cancer services in Prince of Wales and St George public and private hospitals. Through the e-care plan GPs, cancer specialists and patients…